Licensing status

Publication and contact information

Autoimmune disease

Multiple sclerosis (MS)

Granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2); GM-CSF receptor (CSF2RA; GMR; CD116)

Studies in patient samples suggest antagonizing GM-CSF or CSF2RA could help treat MS. Cerebrospinal fluid samples from patients with MS active flares had higher levels of GM-CSF-expressing T helper cells than samples from patients with noninflammatory neurological pathologies. These GM-CSF-expressing T helper cells had higher levels of CNS migration markers than other T helper cell populations. Next steps could include testing the effect of GM-CSF-antagonizing mAbs in cell culture and in mouse models of neuroinflammation and MS.
Amgen Inc.'s anti-GM-CSF mAb, namilumab (MT203), is in Phase I testing for rheumatoid arthritis (RA).

SciBX 7(28); doi:10.1038/scibx.2014.818
Published online July 24, 2014

Patent and licensing status undisclosed

Noster, R. et al. Sci. Transl. Med.; published online June 18, 2014;
Contact: Christina E. Zielinski, Charité-University Hospital Berlin, Berlin, Germany